Author: Zhang, Zhicheng; Wang, Shumei; Tu, Xianglin; Peng, Xuping; Huang, Yanxia; Wang, Li; Ju, Weihua; Rao, Jianfeng; Li, Xue; Zhu, Donghong; Sun, Huabao; Chen, Hongyi
Title: A comparative study on the time to achieve negative nucleic acid testing and hospital stays between Danoprevir and Lopinavir/Ritonavir in the treatment of patients with COVIDâ€19 Cord-id: yrmdjy4p Document date: 2020_6_5
ID: yrmdjy4p
Snippet: BACKGROUND: In late December 2019, the coronavirus disease 2019 (COVIDâ€19) first outbroke in Wuhan city, China, and has now become a global pandemic. However, there is no specific antiviral treatment for COVIDâ€19. METHODS: This study enrolled 33 COVIDâ€19 patients in the nineth hospital of Nanchang from January 27(th) to February 24(th), 2020. Clinical indexes of patients upon admission/discharge were examined. Patients were divided into two groups according to different treatment plans (Da
Document: BACKGROUND: In late December 2019, the coronavirus disease 2019 (COVIDâ€19) first outbroke in Wuhan city, China, and has now become a global pandemic. However, there is no specific antiviral treatment for COVIDâ€19. METHODS: This study enrolled 33 COVIDâ€19 patients in the nineth hospital of Nanchang from January 27(th) to February 24(th), 2020. Clinical indexes of patients upon admission/discharge were examined. Patients were divided into two groups according to different treatment plans (Danoprevir; Lopinavir/Ritonavir). The days to achieve negative nucleic acid testing and the days of hospital stays were counted and statistically analyzed. RESULTS: COVIDâ€19 patients treated with Danoprevir or Lopinavir/Ritonavir were all improved and discharged. Indexes like blood routine, inflammation and immuneâ€related indexes were significantly recovered after treatment. Additionally, under the circumstance that there was no significant difference in patients’ general information between the two groups, we found that the mean time to achieve negative nucleic acid testing and hospital stays of patients treated with Danoprevir both were significantly shorter than those of patients with Lopinavir/Ritonavir. CONCLUSION: Collectively, applying Danoprevir is a good treatment plan for COVIDâ€19 patients. This article is protected by copyright. All rights reserved.
Search related documents:
Co phrase search for related documents- abnormal proportion and admission discharge: 1
- abnormal proportion and admission patient: 1
- abnormal proportion and lopinavir ritonavir: 1, 2, 3
- acid sample and acute sars respiratory syndrome coronavirus: 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17, 18, 19, 20, 21
- acid sample and low mortality: 1
- acid testing and acute sars respiratory syndrome coronavirus: 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17, 18, 19, 20, 21, 22, 23, 24, 25
- acid testing and admission discharge: 1
- acid testing and admission patient: 1, 2, 3, 4
- acid testing and lopinavir ritonavir: 1, 2, 3
- acid testing and low mortality: 1
- actual situation and acute sars respiratory syndrome coronavirus: 1
- actual situation and admission patient: 1
- acute sars respiratory syndrome coronavirus and admission discharge: 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17, 18, 19, 20, 21, 22, 23, 24, 25
- acute sars respiratory syndrome coronavirus and admission patient: 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17, 18, 19, 20, 21, 22, 23, 24, 25
- acute sars respiratory syndrome coronavirus and lopinavir ritonavir: 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17, 18, 19, 20, 21, 22, 23, 24, 25
- acute sars respiratory syndrome coronavirus and low mortality: 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17, 18, 19, 20, 21, 22, 23, 24, 25
- acute sars respiratory syndrome coronavirus and low mortality rate: 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12
- admission discharge and lopinavir ritonavir: 1, 2, 3, 4, 5, 6, 7, 8
- admission discharge and low mortality: 1, 2, 3, 4, 5, 6, 7
Co phrase search for related documents, hyperlinks ordered by date